🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to researchers.

A Global Health Concern

Cases of gonorrhoea are escalating worldwide, with figures suggesting more than 82 million infections each year. Notably increased rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Approval

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This approval signifies a major breakthrough in the management of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Data and Worldwide Availability

Based on findings released by a prominent scientific publication, zoliflodacin successfully treated the vast majority of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which combines an injection and a pill. The research involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in many developing nations.

Clinicians on the front lines have voiced hope. The availability of a one-pill regimen of this kind is seen as a "game-changer" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.